SenzaGen AB

Equities

SENZA

SE0010219626

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm 11:29:48 2024-04-26 am EDT 5-day change 1st Jan Change
6.38 SEK +0.31% Intraday chart for SenzaGen AB +2.90% -12.36%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Senzagen Receives Follow-Up Order Worth SEK 0.8 Million from the Global Chemicals Leader CI
SenzaGen AB Reports Earnings Results for the Full Year Ended December 31, 2023 CI
SenzaGen AB Reports Earnings Results for the Fourth Quarter Ended December 30, 2023 CI
SenzaGen Books Additional Order for Non-animal Skin Sensitization Testing Tool MT
SenzaGen AB Receives A Follow-Up Order Worth SEK 1.5 Million for GARD®Skin for the Chemical Industry CI
SenzaGen Wins SEK2 Million Order for Biotech Product Testing MT
SenzaGen Secures SEK 1.7 Million Order from a New Global Biotech Industry Leader CI
SenzaGen Bags Chemicals Testing Contract MT
Senzagen AB Secures Strategically Important Order from New Customer CI
Transcript : SenzaGen AB - Special Call
SenzaGen Continues to Collaborate with RIFM in Non-Animal Photosensitization and Fragrance Safety CI
SenzaGen AB Reports Earnings Results for the Half Year Ended June 30, 2023 CI
SenzaGen Signs Distribution Deals With French, Indian Companies MT
SenzaGen Strengthens Market Presence with Expanded Distribution Channels CI
SenzaGen AB Reports Consolidated Sales Results for the First Quarter of 2023 CI
SenzaGen AB Wins Order for GARD®skin Worth About SEK 1 Million from A New Chemicals Customer CI
SenzaGen Seeks Acquisitions CI
Transcript : SenzaGen AB, 2022 Earnings Call, Feb 16, 2023
SenzaGen AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2022 CI
SenzaGen AB Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Transcript : SenzaGen AB - Special Call
SenzaGen AB (OM:SENZA) acquired 100% stake in Toxhub S.R.L. for Ç0.3 million. CI
Transcript : SenzaGen AB - Special Call
Transcript : SenzaGen AB, H1 2022 Earnings Call, Aug 18, 2022
SenzaGen AB Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Chart SenzaGen AB
More charts
SenzaGen AB is a Sweden-based company, which specializes in immunology, technology and genomics. The Company markets, sells and performs the in vitro Genomic Allergen Rapid Detection (GARD) sensitization test through its own laboratory and through licensed Contract Research Organization (CROs). SenzaGen AB makes it possible to replace animal experiments with in vitro genetic testing to determine the allergenicity of the chemicals people come in contact with in their daily lives, such as for example in cosmetics, pharmaceuticals, food products and dyes. The Company sells the tests in Sweden and the United States, and also sells through partners in several other countries. SenzaGen AB has a subsidiary in San Francisco, the United States.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. SENZA Stock
  4. News SenzaGen AB
  5. SenzaGen Signs Distribution Deals With French, Indian Companies